---

Cancer Types

Types of Cancer > Myelomas > News

November 2009

Elevated cancer risk seen in relatives of myeloma patients

August 2009

Key role for bisphosphonates in reducing myeloma bone damage

Tandem transplantation effective for untreated multiple myeloma

July 2009

Vitamin D deficiency adversely impacts multiple myeloma

June 2009

Combination therapy effective for previously untreated Waldenström macroglobulinemia

April 2009

High cut-off dialysis useful for myeloma-related renal failure

March 2009

Thalidomide improves myeloma survival after stem cell transplantation

January 2009

Tandem autologous hematopoietic cell transplants do not improve multiple myeloma outcomes

October 2008

Outpatient stem cell transplant feasible for multiple myeloma

August 2008

Bortezomib added to melphalan improves myeloma response

Study clarifies glycoprotein's role in bone damage of multiple myeloma

July 2008

EU agency recommends extended use of Velcade for multiple myeloma

Familial myeloma linked to increased incidence of prostate cancer, MGUS

May 2008

Thalidomide plus dexamethasone: improved primary myeloma therapy

Outlook relatively favorable for younger myeloma patients

Lenalidomide raises clot risk in multiple myeloma patients

April 2008

Association between renal cell cancer and multiple myeloma reported

December 2007

Celgene's Revlimid delays myeloma progression

November 2007

Treatment with lenalidomide enhances survival of relapsed multiple myeloma

October 2007

Lenalidomide plus dexamethasone effective for newly diagnosed multiple myeloma

August 2007

Neuropathy common in multiple myeloma patients treated with thalidomide

June 2007

Survival has improved in multiple myeloma patients

Predictors of multiple myeloma progression identified

Statins potentiate activity of UCN-01 against leukemia and myeloma

May 2007

New bisphosphonate guidelines suggest 2-year treatment in myeloma patients

April 2007

Autografts or allografts the primary unanswered question in multiple myeloma

Bortezomib boosts response in refractory myeloma

Serum proteasomes predict outcomes in multiple myeloma

March 2007

Allograft from HLA-identical sibling improves myeloma survival

November 2006

Bortezomib and thalidomide may benefit elderly with multiple myeloma

August 2006

Bisphosphonates should be used with caution for multiple myeloma

July 2006

Benefits outweigh risks of bortezomib for multiple myeloma

Thalidomide boosts multiple myeloma therapy response

June 2006

US FDA approves Revlimid for multiple myeloma

Multiple myeloma responds to lower thalidomide dose

March 2006

Thalidomide improves chemotherapy efficacy in elderly with multiple myeloma

Adding thalidomide to myeloma therapy of little benefit

January 2006

Thalomid slows multiple myeloma, trial halted -- Celgene

No survival benefit of high dose therapy in multiple myeloma

Oral treatment regimen effective for relapsed multiple myeloma

December 2005

Initial results good in lenalidomide/dexamethasone treatment of multiple myeloma

September 2005

Obesity linked to greater multiple myeloma risk in women

Study supports lenalidomide plus dexamethasone as initial therapy for myeloma

July 2005

Thalidomide more effective than conventional chemotherapy for multiple myeloma

Gaucher disease linked to higher multiple myeloma risk

May 2005

Drug duo acts synergistically to kill multiple myeloma cells in vitro

April 2005

Revlimid delays multiple myeloma progression

March 2005

NF-kappa-B inhibitor acts against multiple myeloma

New multiple myeloma drug meets main goal of trials

December 2004

Diabetes drugs active against myeloma cells

Velcade seen effective in all stages of multiple myeloma

August 2004

Caution needed in thalidomide therapy for myeloma

June 2004

Bortezomib superior to standard therapy for relapsed multiple myeloma

Early second transplant for multiple myeloma may improve outcome

February 2004

Overexpression of c-maf in multiple myeloma makes it attractive therapeutic target

December 2003

Molecule secreted by myeloma cells tied to osteolytic lesions

August 2003

DTPACE is effective induction for autotransplantation in patients with myeloma

July 2003

PEG-L-asparaginase active against refractory multiple myeloma

June 2003

Vitamin D2 analog active against leukemia, myeloma, and colon cancer

May 2003

Intensive therapy improves survival in patients with multiple myeloma

January 2003

Thalidomide effective for previously untreated multiple myeloma

Thalidomide confirmed to have survival benefit in multiple myeloma

December 2002

Pegylated liposomal doxorubicin advantageous in multiple myeloma treatment

Bortezomib/doxorubicin therapy shows significant anti-myeloma activity

Phase II study supports Trisenox in multiple myeloma

November 2002

Flow cytometry accurately monitors multiple myeloma after high-dose therapy

Thalidomide/steroid therapy effective for newly diagnosed multiple myeloma

September 2002

Deep vein thrombosis risk high in myeloma patients treated with doxorubicin and thalidomide

June 2002

Prednisone maintenance therapy improves survival in multiple myeloma

May 2002

Liposomal daunorubicin shows action in multiple myeloma

Ibandronate prolongs survival only in small subgroups of myeloma patients

January 2002

Macrophage inflammatory protein inhibition may curb myeloma bone destruction

December 2001

Tandem transplants increase response in multiple myeloma patients

November 2001

Millennium myeloma drug shows promise in phase I trial

August 2001

Thalidomide regimen for multiple myeloma linked to increased DVT risk

Thalidomide active against Waldenström's macroglobulinemia

New bone marrow transplant approach offers hope for multiple myeloma treatment

July 2001

Thalidomide effective for early-stage multiple myeloma

Response of refractory multiple myeloma to thalidomide spans 2 years

May 2001

Thalidomide better for multiple myeloma if combined with other drugs

Patients with advanced multiple myeloma improve on arsenic trioxide therapy

March 2001

Millennium begins phase II trial of multiple myeloma drug

February 2001

Bone growth factor inhibits proliferation of multiple myeloma cells

September 2000

Celgene's Thalomid offers benefit in late-stage multiple myeloma

July 2000

Vaccine based on dendritic cells appears safe in early trials of multiple myeloma

Thalidomide induces response in large series of multiple myeloma patients

June 2000

Negative immunofixation predicts good outcome for multiple myeloma patients

Molecular remission of multiple myeloma linked to longer disease control

Immunotherapy is feasible therapeutic approach to multiple myeloma

March 2000

Thalidomide benefits patients with multiple myeloma

January 2000

High-dose chemotherapy with stem cell transplant benefits younger myeloma patients

March 1999

Tumor purging by CD34-selection effective for multiple myeloma patients after chemotherapy

Octreotide inhibits growth of multiple myeloma cells

Kaposi's sarcoma herpesvirus DNA detected in patients with multiple myeloma